Quince Therapeutics renamed IRulya; Roberts named CEO, Militello CFO, Fandrick COO effective Oct 8, 2026

Quince Therapeutics, Inc.

Brigette Roberts, M.D. became CEO effective Oct 8, 2026 with $600,000 base salary and 50% target bonus; John Militello, CPA became CFO and Keith Fandrick, Ph.D. became COO.
Dirk Thye resigned as CEO, CMO and director and Brendan Hannah resigned as COO, CBO and CCO; June Bray, David Lamond, Christopher Senner and Thye also left the Board with no disagreements.
Name change to IRulya Therapeutics Inc. is effective 4:01 p.m. ET Oct 9, 2026; common stock moves to Nasdaq Capital Market under IRLA effective Oct 12, 2026, with CUSIP unchanged.
Cash balance was $116 million as of June 30, 2026 and is expected to fund operations through end of 2028, supporting Phase 2 data readouts for LAM-001 in BOS, PH-ILD and SAPH.
Board added Catherine Bonuccelli, Leone Patterson, James Valentine and Drayton Wise effective Oct 8, 2026; Patterson chairs Audit/Compensation, Valentine chairs Governance.

item 5.02 item 5.03 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dirk Thye

Chief Executive Officer, Chief Medical Officer and Director

QNCX · Quince Therapeutics, Inc.

Effective: 2026-10-08
Successor: Brigette Roberts
Filed: October 9, 2026, 7:59 AM ET

effective as of October 8, 2026, Dirk Thye, M.D., resigned as Chief Executive Officer and Chief Medical Officer, as well as a director, of Quince Therapeutics, Inc.

Departed

Brendan Hannah

Chief Operating Officer, Chief Business Officer and Chief Compliance Officer

QNCX · Quince Therapeutics, Inc.

Effective: 2026-10-08
Successor: Keith Fandrick
Filed: October 9, 2026, 7:59 AM ET

Brendan Hannah resigned as Chief Operating Officer, Chief Business Officer and Chief Compliance Officer of the Company.

Appointed

Brigette Roberts

Chief Executive Officer

QNCX · Quince Therapeutics, Inc.

Effective: 2026-10-08
Filed: October 9, 2026, 7:59 AM ET

Effective October 8, 2026 (the “ Effective Date ”), the Board of Directors (the “ Board ”) of the Company appointed Brigette Roberts, M.D., as Chief Executive Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dirk Thye resigned as Chief Executive Officer, Chief Medical Officer and Director at Quince Therapeutics, Inc..

Action: resigned
Role: Chief Executive Officer, Chief Medical Officer and Director

Exact text from the filing

effective as of October 8, 2026, Dirk Thye, M.D., resigned as Chief Executive Officer and Chief Medical Officer, as well as a director, of Quince Therapeutics, Inc.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.8

Brendan Hannah resigned as Chief Operating Officer, Chief Business Officer and Chief Compliance Officer at Quince Therapeutics, Inc..

Action: resigned
Role: Chief Operating Officer, Chief Business Officer and Chief Compliance Officer

Exact text from the filing

Brendan Hannah resigned as Chief Operating Officer, Chief Business Officer and Chief Compliance Officer of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Brigette Roberts was appointed as Chief Executive Officer at Quince Therapeutics, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

Effective October 8, 2026 (the “ Effective Date ”), the Board of Directors (the “ Board ”) of the Company appointed Brigette Roberts, M.D., as Chief Executive Officer of the Company.

View on SEC.gov

Quince Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-418538

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.